Keeler, a world leader in ophthalmic diagnostic, digital, surgical, and clinical products is proud to announce our partnership with Long Grove Pharmaceuticals® . Long Grove Pharmaceuticals® was established in 2019 by Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. Long Grove Pharmaceuticals® acquired the rights to AK-FLUOR® in both 10% and 25% formulations from Akorn Pharmaceuticals in May 2023. To ensure the consistent availability of AK-FLUOR® prior to its relaunch as a Long Grove Pharmaceuticals® product, Long Grove reached a distribution agreement with the FDA Office of Drug Shortages through the Regulatory Discretion Process and has made available the existing AK-FLUOR® inventory manufactured by Akorn Pharmaceuticals.
“We are excited to supply AK-FLUOR® to our customers within the United States by partnering with Long Grove Pharmaceuticals® ,” says Keeler, John Risley, Sales Director “Our key focus is to work together and be able to bring this product to customers who have had a hard time sourcing this since it has been on the FDA drug shortage list. “Our new relationship with Keeler is aimed at easing the procurement burdens of this essential ophthalmic drug.,” said Peter Karas, Chief Commercial Officer of Long Grove Pharmaceuticals®. “Our goal is to provide the market consistent supply of this medication now and after it’s relaunch as a Long Grove product.”